CAPTRUST Financial Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History
Bought
Maintained
Sold
Other funds holding BIB
CIA
TFA
CG
IA
CAPTRUST Financial Advisors's BIB Position: Q3 2022 in Review
CAPTRUST Financial Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2022, closing a stake of 180 shares — an estimated $9K sold.
CAPTRUST Financial Advisors first reported a position in BIB in Q2 2017 and held it in 19 quarters. The position peaked at $18K in Q2 2021. 19 funds tracked by Wall St. Rank hold BIB as of Q3 2022.
- CAPTRUST Financial Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2022 after selling out during the quarter.
- CAPTRUST Financial Advisors sold 180 ProShares Ultra NASDAQ Biotechnology shares in Q3 2022, an estimated $9K.
- CAPTRUST Financial Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2017 and held it in 19 quarters.
- CAPTRUST Financial Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $18K in Q2 2021.
- 19 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2022.
Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.